-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Dow Jones·07/20/2026 12:30:00

Please log in to view news